Profile: Pluristem Therapeutics, Inc. (PSTI.O)

Pluristem Therapeutics Inc., incorporated on May 11, 2001, is a bio-therapeutics company engaged in developing and intending to commercialize, cell therapy production technologies and products. The Company focuses on commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products, stored ready to use, that are derived from human placenta, a non-controversial, non-embryonic adult stromal cell source. The Company’s focuses in the development of product candidates for local administration for indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.

The Company focuses on developing Placenta expanded cells- peripheral artery disease (PLX-PAD) cells as an allogeneic therapeutic product to treat CLI which results from PAD. As of June 2009, the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, approved its clinical trial application (CTA) and granted approval it to begin clinical trials of PLX-PAD. As of July 2009, the first patient was enrolled in a Phase I clinical trial of its PLX-PAD product at the Franziskus-Krankenhaus Hospital, Berlin. In July 2009, the first patient was enrolled in a Phase I clinical trial of its PLX-PAD product at the Franziskus-Krankenhaus Hospital, Berlin.

The Company competes with Osiris Therapeutics, Aastrom Biosciences, Cytori Therapeutics, Gamida Cell, Geron, Mesoblast and Celgene.